X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs JUBILANT LIFE SCIENCES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA JUBILANT LIFE SCIENCES AJANTA PHARMA/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 19.2 20.6 93.3% View Chart
P/BV x 7.7 5.0 154.4% View Chart
Dividend Yield % 0.8 0.4 213.7%  

Financials

 AJANTA PHARMA   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
JUBILANT LIFE SCIENCES
Mar-14
AJANTA PHARMA/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs1,720187 920.8%   
Low Rs1,10365 1,694.3%   
Sales per share (Unadj.) Rs194.6364.3 53.4%  
Earnings per share (Unadj.) Rs45.26.8 660.5%  
Cash flow per share (Unadj.) Rs50.324.5 205.3%  
Dividends per share (Unadj.) Rs8.003.00 266.7%  
Dividend yield (eoy) %0.62.4 23.8%  
Book value per share (Unadj.) Rs132.0164.9 80.1%  
Shares outstanding (eoy) m88.77159.28 55.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.30.3 2,098.2%   
Avg P/E ratio x31.218.4 169.7%  
P/CF ratio (eoy) x28.15.1 545.9%  
Price / Book Value ratio x10.70.8 1,399.6%  
Dividend payout %17.743.8 40.4%   
Avg Mkt Cap Rs m125,29920,061 624.6%   
No. of employees `000NA6.2 0.0%   
Total wages/salary Rs m2,57011,052 23.3%   
Avg. sales/employee Rs ThNM9,383.0-  
Avg. wages/employee Rs ThNM1,786.9-  
Avg. net profit/employee Rs ThNM176.3-  
INCOME DATA
Net Sales Rs m17,27558,034 29.8%  
Other income Rs m166191 87.3%   
Total revenues Rs m17,44258,224 30.0%   
Gross profit Rs m5,8075,786 100.4%  
Depreciation Rs m4512,812 16.0%   
Interest Rs m493,237 1.5%   
Profit before tax Rs m5,474-72 -7,592.2%   
Minority Interest Rs m0-286 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m02,145 0.0%   
Tax Rs m1,460696 209.6%   
Profit after tax Rs m4,0141,090 368.1%  
Gross profit margin %33.610.0 337.2%  
Effective tax rate %26.7-965.9 -2.8%   
Net profit margin %23.21.9 1,236.7%  
BALANCE SHEET DATA
Current assets Rs m7,63929,280 26.1%   
Current liabilities Rs m2,71538,912 7.0%   
Net working cap to sales %28.5-16.6 -171.7%  
Current ratio x2.80.8 373.9%  
Inventory Days Days4384 51.2%  
Debtors Days Days7951 155.2%  
Net fixed assets Rs m6,91455,712 12.4%   
Share capital Rs m177155 114.5%   
"Free" reserves Rs m11,44220,968 54.6%   
Net worth Rs m11,72126,265 44.6%   
Long term debt Rs m14917,169 0.9%   
Total assets Rs m14,81488,606 16.7%  
Interest coverage x112.91.0 11,551.6%   
Debt to equity ratio x00.7 1.9%  
Sales to assets ratio x1.20.7 178.0%   
Return on assets %27.44.9 561.5%  
Return on equity %34.24.2 825.0%  
Return on capital %46.511.6 402.3%  
Exports to sales %55.137.8 145.9%   
Imports to sales %6.016.5 36.4%   
Exports (fob) Rs m9,52721,933 43.4%   
Imports (cif) Rs m1,0389,567 10.8%   
Fx inflow Rs m10,42222,004 47.4%   
Fx outflow Rs m1,67811,749 14.3%   
Net fx Rs m8,74410,255 85.3%   
CASH FLOW
From Operations Rs m3,2648,026 40.7%  
From Investments Rs m-2,093-1,744 120.0%  
From Financial Activity Rs m-1,186-4,447 26.7%  
Net Cashflow Rs m-151,834 -0.8%  

Share Holding

Indian Promoters % 73.8 45.6 161.8%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 1.6 8.7 17.8%  
FIIs % 7.6 21.2 35.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 21.1 80.6%  
Shareholders   20,968 23,815 88.0%  
Pledged promoter(s) holding % 4.4 15.9 27.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   UNICHEM LAB  AUROBINDO PHARMA  IPCA LABS  GLENMARK PHARMA  VENUS REMEDIES  

Compare AJANTA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Of Cheap Valuation of PSU Banks and Key Stocks in Action Today(Pre-Open)

NSE PSU Bank Index surged 30% on 25th October 2017-the date when bank recapitalization of Rs 2.1 trillion was announced.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Looking Beyond the Colourful Prism of This Airline Company(Sector Info)

May 10, 2018

Can Interglobe Aviation Safely Fly Out of Turbulence?

HDFC Prudence Fund Now HDFC Balanced Advantage Fund - Time To Sell?(Outside View)

May 9, 2018

PersonalFN provides detail analysis on HDFC Balanced Advantage Fund (erstwhile HDFC Prudence Fund and HDFC Growth Fund).

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


May 18, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - MERCK LTD COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS